<DOC>
	<DOCNO>NCT00109343</DOCNO>
	<brief_summary>The study conduct demonstrate V221 may administer concomitantly pneumococcal conjugate vaccine without impair safety immunogenicity measles , mumps , rubella , varicella , 7 serotypes S. pneumoniae .</brief_summary>
	<brief_title>V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine ( V221-019 )</brief_title>
	<detailed_description />
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>In good health 12 15 month age Negative clinical history measles , mumps , rubella , varicella and/or zoster Received 3dose primary series pneumococcal conjugate vaccine least 2 month prior receipt study vaccine Signed consent Previous administration measles , mumps , rubella , varicella vaccine either alone combination Any condition result depressed immunity Any allergy vaccine component state package circular Exposure measles , mumps , rubella , varicella , zoster within 4 week prior study vaccination History seizure disorder Receipt inactivate vaccine within 14 day prior enrollment live vaccine within 30 day Recent febrile illness</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>